GP2D Cells
USD$800.00*
Products are shipped frozen on dry ice in cryotubes. Each cryotube typically contains 3 × 106 cells for adherent lines or 5 × 106 cells for suspension lines (refer to the batch CoA for details).
General information
| Description | GP2d is a human colorectal adenocarcinoma cell line derived from a poorly differentiated colon tumor. It was established alongside a sister line, GPSd, from the same adenocarcinoma specimen. While both lines share similar genetic alterations consistent with common patterns seen in colorectal cancer, including an inverted duplication involving chromosome 10q11-q21, they differ markedly in their phenotypic characteristics and cellular behavior. Notably, no translocations involving the ret proto-oncogene-mapped to this chromosomal region-were detected by Southern blot analysis, suggesting the duplication did not disrupt this gene directly. GP2d cells exhibit a cohesive, spreading growth pattern from the edges of microcolonies to form a confluent epithelial monolayer. This morphology is accompanied by distinct expression patterns of adhesion molecules such as α2-integrin, desmoplakin, and E-cadherin, all of which play roles in maintaining epithelial integrity. Functionally, GP2d cells respond robustly to epidermal growth factor (EGF), transforming growth factor-alpha (TGFα), and insulin, as demonstrated by increased cell proliferation in response to these ligands. Interestingly, both GP2d and GPSd express comparable numbers of EGF receptors, but differ in their expression of EGF receptor ligands. GP2d cells have abundant amphiregulin mRNA, whereas GPSd predominantly expresses TGFα mRNA with little to no amphiregulin, correlating with the differing biological responses observed. These features make GP2d a valuable model for studying the regulation of growth factor signaling and cell adhesion in colorectal cancer. Its responsiveness to EGF pathway stimuli and distinct epithelial morphology highlight its utility in investigating tumor cell differentiation and proliferation. Furthermore, the shared origin with GPSd allows for comparative studies of clonal variation within tumors, particularly in the context of ligand-receptor dynamics and epithelial-to-mesenchymal transition (EMT) responses. |
|---|---|
| Organism | Human |
| Tissue | Colon |
| Disease | Colon adenocarcinoma |
| Synonyms | Gp2d, Gp2D, GP2D |
Characteristics
| Age | 71 years |
|---|---|
| Gender | Female |
| Ethnicity | Caucasian |
Regulatory Data
| Citation | GP2D (Cytion catalog number 305778) |
|---|---|
| NCBI_TaxID | 9606 |
| CellosaurusAccession | CVCL_2450 |
Biomolecular Data
| Mutational profile | Mutation: KRAS, Simple, p.Gly12Asp (c.35G>A), Heterozygous, TP53 |
|---|
Handling
| Freeze medium | As a cryopreservation medium, we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. |
|---|---|
| Thawing and Culturing Cells |
|
| Incubation Atmosphere | 37°C, 5% CO2, humidified atmosphere. |
| Shipping Conditions | Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage. |
| Storage Conditions | For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen. |
Quality Control & Molecular Analysis
| Sterility | Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. |
|---|
Certificate of Analysis (CoA)
| Lot Number | Certificate Type | Date | Catalog Number |
|---|---|---|---|
| 305778-200426 | Certificate of Analysis | 15. May. 2026 | 305778 |